{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:47:38Z","timestamp":1790383658955,"version":"4.1.0"},"reference-count":133,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014899","name":"American Neurogastroenterology and Motility Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014899","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gastrojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1053\/j.gastro.2025.12.040","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T12:22:11Z","timestamp":1771503731000},"page":"1388-1407","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Design of Treatment Trials for Disorders of Gut\u2013Brain Interaction"],"prefix":"10.1053","volume":"170","author":[{"given":"Gregory S.","family":"Sayuk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren M.","family":"Brenner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florencia","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon R.","family":"Knowles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian E.","family":"Lacy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi M.","family":"Staudacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander C.","family":"Ford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.gastro.2025.12.040_bib1","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1136\/gutjnl-2019-320325","article-title":"Actionable biomarkers: the key to resolving disorders of gastrointestinal function","volume":"69","author":"Camilleri","year":"2020","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2025.12.040_bib2","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/S2468-1253(23)00102-4","article-title":"Overlap of disorders of gut-brain interaction: a systematic review and meta-analysis","volume":"8","author":"Fairlie","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2025.12.040_bib3","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S2468-1253(21)00131-X","article-title":"Irritable bowel syndrome: a spotlight on future research needs","volume":"6","author":"Black","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2025.12.040_bib4","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S2468-1253(21)00023-6","article-title":"The placebo response rate in pharmacological trials in patients with irritable bowel syndrome: a systematic review and meta-analysis","volume":"6","author":"Bosman","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2025.12.040_bib5","doi-asserted-by":"crossref","DOI":"10.1111\/nmo.14474","article-title":"Placebo response in pharmacological trials in patients with functional dyspepsia\u2014a systematic review and meta-analysis","volume":"35","author":"Bosman","year":"2023","journal-title":"Neurogastroenterol Motil"},{"key":"10.1053\/j.gastro.2025.12.040_bib7","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Schulz","year":"1995","journal-title":"JAMA"},{"key":"10.1053\/j.gastro.2025.12.040_bib8","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.cct.2010.11.004","article-title":"The blind leading the blind: use and misuse of blinding in randomized controlled trials","volume":"32","author":"Miller","year":"2011","journal-title":"Contemp Clin Trials"},{"key":"10.1053\/j.gastro.2025.12.040_bib9","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.cct.2003.10.016","article-title":"Assessment of blinding in clinical trials","volume":"25","author":"Bang","year":"2004","journal-title":"Control Clin Trials"},{"key":"10.1053\/j.gastro.2025.12.040_bib10","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1136\/bmj.323.7310.446","article-title":"Statistics notes: Concealing treatment allocation in randomised trials","volume":"323","author":"Altman","year":"2001","journal-title":"BMJ"},{"key":"10.1053\/j.gastro.2025.12.040_bib11","first-page":"374","article-title":"Understanding the placebo and nocebo effects in patients with irritable bowel syndrome","volume":"16","author":"Lembo","year":"2020","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"10.1053\/j.gastro.2025.12.040_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/omi.2020.0208","article-title":"Rethinking clinical trials and personalized medicine with placebogenomics and placebo dose","volume":"25","author":"\u00d6zdemir","year":"2021","journal-title":"OMICS"},{"key":"10.1053\/j.gastro.2025.12.040_bib13","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/nrgastro.2015.117","article-title":"Placebo effects and their determinants in gastrointestinal disorders","volume":"12","author":"Elsenbruch","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2025.12.040_bib14","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/j.1365-2036.2010.04328.x","article-title":"Meta-analysis: factors affecting placebo response rate in the irritable bowel syndrome","volume":"32","author":"Ford","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2025.12.040_bib15","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1097\/MCG.0000000000001575","article-title":"Improving medication tolerance: a pilot study in disorders of gut-brain interaction treated with tricyclic antidepressants","volume":"56","author":"Ballou","year":"2022","journal-title":"J Clin Gastroenterol"},{"key":"10.1053\/j.gastro.2025.12.040_bib16","article-title":"Nocebo response intensity and influencing factors in the randomized clinical trials of irritable bowel syndrome: a systematic review and meta-analysis","volume":"9","author":"Li","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"10.1053\/j.gastro.2025.12.040_bib17","doi-asserted-by":"crossref","first-page":"692","DOI":"10.14309\/ajg.0000000000002108","article-title":"Examining the nocebo effect in trials of neuromodulators for use in disorders of gut-brain interaction","volume":"118","author":"Glissen Brown","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2025.12.040_bib18","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1001\/jamainternmed.2013.6705","article-title":"The effect of treatment history on therapeutic outcome: an experimental approach","volume":"173","author":"Kessner","year":"2013","journal-title":"JAMA Intern Med"},{"key":"10.1053\/j.gastro.2025.12.040_bib19","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3001244","article-title":"The effect of treatment expectation on drug efficacy: imaging the analgesic benefit of the opioid remifentanil","volume":"3","author":"Bingel","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1053\/j.gastro.2025.12.040_bib20","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2147\/CLEP.S188752","article-title":"Randomized clinical trials with run-in periods: frequency, characteristics and reporting","volume":"11","author":"Laursen","year":"2019","journal-title":"Clin Epidemiol"},{"key":"10.1053\/j.gastro.2025.12.040_bib21","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1186\/s13063-016-1451-9","article-title":"Randomized controlled trials: who fails run-in?","volume":"17","author":"Rees","year":"2016","journal-title":"Trials"},{"key":"10.1053\/j.gastro.2025.12.040_bib22","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1111\/apt.16027","article-title":"Letter: placebo run-in for IBS clinical trials-is it useful?","volume":"52","author":"Bosman","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2025.12.040_bib24","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0140-6736(23)01523-4","article-title":"Amitriptyline at Low-Dose and Titrated for Irritable Bowel Syndrome as Second-Line Treatment in primary care (ATLANTIS): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"402","author":"Ford","year":"2023","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2025.12.040_bib26","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1017\/S0029665117002816","article-title":"The challenges of control groups, placebos and blinding in clinical trials of dietary interventions","volume":"76","author":"Staudacher","year":"2017","journal-title":"Proc Nutr Soc"},{"key":"10.1053\/j.gastro.2025.12.040_bib27","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1053\/j.gastro.2021.09.015","article-title":"A Rome Working Team Report on brain-gut behavior therapies for disorders of gut-brain interaction","volume":"162","author":"Keefer","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2025.12.040_bib28","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S2468-1253(23)00398-9","article-title":"Efficacy and safety of linaclotide in treating functional constipation in paediatric patients: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial","volume":"9","author":"Di Lorenzo","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2025.12.040_bib29","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/MPG.0000000000003191","article-title":"A collaborative effort to advance drug development in pediatric constipation and irritable bowel syndrome","volume":"73","author":"Saps","year":"2021","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1053\/j.gastro.2025.12.040_bib30","doi-asserted-by":"crossref","DOI":"10.1111\/nmo.13294","article-title":"Recommendations for pharmacological clinical trials in children with functional constipation: the Rome Foundation Pediatric Subcommittee on Clinical Trials","volume":"30","author":"Koppen","year":"2018","journal-title":"Neurogastroenterol Motil"},{"key":"10.1053\/j.gastro.2025.12.040_bib31","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1111\/nmo.12896","article-title":"Recommendations for pharmacological clinical trials in children with irritable bowel syndrome: the Rome Foundation Pediatric Subcommittee on Clinical Trials","volume":"28","author":"Saps","year":"2016","journal-title":"Neurogastroenterol Motil"},{"key":"10.1053\/j.gastro.2025.12.040_bib33","series-title":"Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021)","article-title":"Patient-reported outcomes","author":"Johnson","year":"2021"},{"key":"10.1053\/j.gastro.2025.12.040_bib34","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1136\/bmj.305.6846.160","article-title":"Validating the SF-36 health survey questionnaire: new outcome measure for primary care","volume":"305","author":"Brazier","year":"1992","journal-title":"BMJ"},{"key":"10.1053\/j.gastro.2025.12.040_bib35","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1023\/A:1018831127942","article-title":"Quality of life in persons with irritable bowel syndrome: development and validation of a new measure","volume":"43","author":"Patrick","year":"1998","journal-title":"Dig Dis Sci"},{"key":"10.1053\/j.gastro.2025.12.040_bib36","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1111\/j.1365-2036.2010.04464.x","article-title":"Measuring symptoms in the irritable bowel syndrome: development of a framework for clinical trials","volume":"32","author":"Spiegel","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2025.12.040_bib38","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1053\/j.gastro.2016.02.031","article-title":"Bowel disorders","volume":"150","author":"Mearin","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2025.12.040_bib40","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.jval.2016.11.001","article-title":"Development of the diary for irritable bowel syndrome symptoms to assess treatment benefit in clinical trials: foundational qualitative research","volume":"20","author":"Fehnel","year":"2017","journal-title":"Value Health"},{"key":"10.1053\/j.gastro.2025.12.040_bib41","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1056\/NEJMoa0800670","article-title":"A placebo-controlled trial of prucalopride for severe chronic constipation","volume":"358","author":"Camilleri","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2025.12.040_bib42","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1136\/gut.2008.162404","article-title":"Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives","volume":"58","author":"Tack","year":"2009","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2025.12.040_bib43","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1136\/gut.32.1.73","article-title":"How bad are the symptoms and bowel dysfunction of patients with the irritable bowel syndrome? A prospective, controlled study with emphasis on stool form","volume":"32","author":"Heaton","year":"1991","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2025.12.040_bib44","first-page":"26","article-title":"An examination of the reliability of reported stool frequency in the diagnosis of idiopathic constipation","volume":"91","author":"Ashraf","year":"1996","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2025.12.040_bib45","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/apt.13753","article-title":"Validation of the Leuven Postprandial Distress Scale, a questionnaire for symptom assessment in the functional dyspepsia\/postprandial distress syndrome","volume":"44","author":"Carbone","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2025.12.040_bib46","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/ajg.2017.265","article-title":"Development of a symptom-focused patient-reported outcome measure for functional dyspepsia: the Functional Dyspepsia Symptom Diary (FDSD)","volume":"113","author":"Taylor","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2025.12.040_bib47","doi-asserted-by":"crossref","DOI":"10.1111\/nmo.13496","article-title":"Development of a real-time patient-reported outcome measure for symptom assessment in patients with functional dyspepsia using the experience sampling method","volume":"31","author":"Smeets","year":"2019","journal-title":"Neurogastroenterol Motil"},{"key":"10.1053\/j.gastro.2025.12.040_bib49","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.cgh.2007.03.004","article-title":"Primary endpoints for irritable bowel syndrome trials: a review of performance of endpoints","volume":"5","author":"Camilleri","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2025.12.040_bib50","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1177\/030006059802600203","article-title":"Adequate relief as an endpoint in clinical trials in irritable bowel syndrome","volume":"26","author":"Mangel","year":"1998","journal-title":"J Int Med Res"},{"key":"10.1053\/j.gastro.2025.12.040_bib51","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1572-0241.2003.07158.x","article-title":"Outcome measures in irritable bowel syndrome: comparison of psychometric and methodological characteristics","volume":"98","author":"Bijkerk","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2025.12.040_bib52","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/clpt.2008.128","article-title":"The use of patient-reported outcome measures in the evaluation of medical products for regulatory approval","volume":"84","author":"Burke","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1053\/j.gastro.2025.12.040_bib53","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1053\/j.gastro.2023.11.307","article-title":"Patient-reported outcomes in disorders of gut-brain interaction","volume":"166","author":"Tack","year":"2024","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2025.12.040_bib54","doi-asserted-by":"crossref","DOI":"10.1111\/nmo.70019","article-title":"The Waiting Room Questionnaire, a patient-reported outcome instrument including pictograms for facilitating the diagnosis of functional gastrointestinal disorders","volume":"37","author":"Goelen","year":"2025","journal-title":"Neurogastroenterol Motil"},{"key":"10.1053\/j.gastro.2025.12.040_bib55","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/apt.12855","article-title":"The use of pictograms improves symptom evaluation by patients with functional dyspepsia","volume":"40","author":"Tack","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2025.12.040_bib56","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1038\/ajg.2014.237","article-title":"Development of the NIH Patient-Reported Outcomes Measurement Information System (PROMIS) gastrointestinal symptom scales","volume":"109","author":"Spiegel","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2025.12.040_bib57","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1159\/000079707","article-title":"Evaluation of GERD symptoms during therapy. Part I. Development of the new GERD questionnaire ReQuest","volume":"69","author":"Bardhan","year":"2004","journal-title":"Digestion"},{"key":"10.1053\/j.gastro.2025.12.040_bib58","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1111\/j.1365-2036.2009.04142.x","article-title":"Development of the GerdQ, a tool for the diagnosis and management of gastro-oesophageal reflux disease in primary care","volume":"30","author":"Jones","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2025.12.040_bib59","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1477-7525-6-31","article-title":"The Reflux Disease Questionnaire: a measure for assessment of treatment response in clinical trials","volume":"6","author":"Shaw","year":"2008","journal-title":"Health Qual Life Outcomes"},{"key":"10.1053\/j.gastro.2025.12.040_bib60","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1155\/2003\/530984","article-title":"Validation of the GSFQ, a self-administered symptom frequency questionnaire for patients with gastroesophageal reflux disease","volume":"17","author":"Pare","year":"2003","journal-title":"Can J Gastroenterol"},{"key":"10.1053\/j.gastro.2025.12.040_bib61","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/j.1365-2036.2008.03922.x","article-title":"International validation of a health-related quality of life questionnaire in patients with erosive gastro-oesophageal reflux disease","volume":"29","author":"Holtmann","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2025.12.040_bib62","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1023\/A:1005558204440","article-title":"Patient-based assessment in dyspepsia: development and validation of Dyspepsia Symptom Severity Index (DSSI)","volume":"45","author":"Leidy","year":"2000","journal-title":"Dig Dis Sci"},{"key":"10.1053\/j.gastro.2025.12.040_bib63","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1046\/j.1365-2036.1998.00404.x","article-title":"The Leeds Dyspepsia Questionnaire: a valid tool for measuring the presence and severity of dyspepsia","volume":"12","author":"Moayyedi","year":"1998","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2025.12.040_bib64","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1097\/00042737-199610000-00006","article-title":"The Glasgow Dyspepsia Severity Score\u2014a tool for the global measurement of dyspepsia","volume":"8","author":"el-Omar","year":"1996","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2025.12.040_bib65","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1111\/apt.13378","article-title":"Systematic review: instruments to assess abdominal pain in irritable bowel syndrome","volume":"42","author":"Mujagic","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2025.12.040_bib66","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1111\/nmo.12624","article-title":"The Experience Sampling Method\u2014a new digital tool for momentary symptom assessment in IBS: an exploratory study","volume":"27","author":"Mujagic","year":"2015","journal-title":"Neurogastroenterol Motil"},{"key":"10.1053\/j.gastro.2025.12.040_bib67","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1038\/ajg.2011.170","article-title":"Characterization of episodes of irritable bowel syndrome using ecological momentary assessment","volume":"106","author":"Weinland","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2025.12.040_bib68","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/j.pain.2014.05.009","article-title":"Effect of variability in the 7-day baseline pain diary on the assay sensitivity of neuropathic pain randomized clinical trials: an ACTTION study","volume":"155","author":"Farrar","year":"2014","journal-title":"Pain"},{"key":"10.1053\/j.gastro.2025.12.040_bib69","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.pmn.2019.05.003","article-title":"The differentiation between pain and discomfort: a concept analysis of discomfort","volume":"20","author":"Ashkenazy","year":"2019","journal-title":"Pain Manag Nurs"},{"key":"10.1053\/j.gastro.2025.12.040_bib70","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1111\/j.1572-0241.2002.07110.x","article-title":"Is there a difference between abdominal pain and discomfort in moderate to severe IBS patients?","volume":"97","author":"Sach","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2025.12.040_bib71","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1111\/j.1572-0241.2001.05336.x","article-title":"Sensation of bloating and visible abdominal distension in patients with irritable bowel syndrome","volume":"96","author":"Chang","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2025.12.040_bib72","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/j.1365-2036.2011.04637.x","article-title":"Review article: the treatment of functional abdominal bloating and distension","volume":"33","author":"Schmulson","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2025.12.040_bib73","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1053\/j.gastro.2006.07.015","article-title":"Relationship of abdominal bloating to distention in irritable bowel syndrome and effect of bowel habit","volume":"131","author":"Houghton","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2025.12.040_bib74","doi-asserted-by":"crossref","DOI":"10.1111\/nmo.14330","article-title":"Development and validation of a novel scoring system for bloating and distension: the Mayo Bloating Questionnaire","volume":"34","author":"Lacy","year":"2022","journal-title":"Neurogastroenterol Motil"},{"key":"10.1053\/j.gastro.2025.12.040_bib75","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1136\/gut.48.2.216","article-title":"Ambulatory abdominal inductance plethysmography: towards objective assessment of abdominal distension in irritable bowel syndrome","volume":"48","author":"Lewis","year":"2001","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2025.12.040_bib76","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1111\/apt.14349","article-title":"The PAC-SYM questionnaire for chronic constipation: defining the minimal important difference","volume":"46","author":"Yiannakou","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2025.12.040_bib77","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/ajg.2010.431","article-title":"Validation of a bowel function diary for assessing opioid-induced constipation","volume":"106","author":"Camilleri","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2025.12.040_bib78","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1046\/j.1365-2036.1997.142318000.x","article-title":"The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress","volume":"11","author":"Francis","year":"1997","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2025.12.040_bib79","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1080\/00365520310004209","article-title":"An irritable bowel syndrome-specific symptom questionnaire: development and validation","volume":"38","author":"Wiklund","year":"2003","journal-title":"Scand J Gastroenterol"},{"key":"10.1053\/j.gastro.2025.12.040_bib80","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/j.1445-5994.1995.tb01894.x","article-title":"Initial validation of a bowel symptom questionnaire and measurement of chronic gastrointestinal symptoms in Australians","volume":"25","author":"Talley","year":"1995","journal-title":"Aust N Z J Med"},{"key":"10.1053\/j.gastro.2025.12.040_bib82","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/nmo.12151","article-title":"FDA and EMA end points: which outcome end points should we use in clinical trials in patients with irritable bowel syndrome?","volume":"25","author":"Corsetti","year":"2013","journal-title":"Neurogastroenterol Motil"},{"key":"10.1053\/j.gastro.2025.12.040_bib83","first-page":"9","article-title":"Urgency as an endpoint in irritable bowel syndrome","volume":"4","author":"Mangel","year":"2011","journal-title":"Gastroenterology Res"},{"key":"10.1053\/j.gastro.2025.12.040_bib84","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S1542-3565(04)00284-8","article-title":"Effect of alosetron on bowel urgency and global symptoms in women with severe, diarrhea-predominant irritable bowel syndrome: analysis of two controlled trials","volume":"2","author":"Lembo","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2025.12.040_bib85","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1136\/gut.44.1.77","article-title":"Prospective comparison of faecal incontinence grading systems","volume":"44","author":"Vaizey","year":"1999","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2025.12.040_bib86","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1038\/ajg.2009.203","article-title":"Supragastric belching in patients with reflux symptoms","volume":"104","author":"Hemmink","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2025.12.040_bib87","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/ajg.2018.15","article-title":"Treatment of supragastric belching with cognitive behavioral therapy improves quality of life and reduces acid gastroesophageal reflux","volume":"113","author":"Glasinovic","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2025.12.040_bib88","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/jcag\/gwy010","article-title":"The use of standardized questions in identifying patients with dyssynergic defecation","volume":"1","author":"Parker","year":"2018","journal-title":"J Can Assoc Gastroenterol"},{"key":"10.1053\/j.gastro.2025.12.040_bib89","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0022-3999(94)00104-D","article-title":"Globus pharyngis: development of a symptom assessment scale","volume":"39","author":"Deary","year":"1995","journal-title":"J Psychosom Res"},{"key":"10.1053\/j.gastro.2025.12.040_bib90","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1442-2050.2007.00670.x","article-title":"Validation of the Mayo Dysphagia Questionnaire","volume":"20","author":"Grudell","year":"2007","journal-title":"Dis Esophagus"},{"key":"10.1053\/j.gastro.2025.12.040_bib91","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1111\/j.1572-0241.1999.01272.x","article-title":"Health-related quality of life: a primer for gastroenterologists","volume":"94","author":"Eisen","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2025.12.040_bib92","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1477-7525-4-79","volume":"4","year":"2006","journal-title":"Health Qual Life Outcomes"},{"key":"10.1053\/j.gastro.2025.12.040_bib93","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item Short-Form Health Survey (SF-36). I. Conceptual framework and item selection","volume":"30","author":"Ware","year":"1992","journal-title":"Med Care"},{"key":"10.1053\/j.gastro.2025.12.040_bib94","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1136\/bmj.306.6890.1437","article-title":"Short form 36 (SF36) health survey questionnaire: normative data for adults of working age","volume":"306","author":"Jenkinson","year":"1993","journal-title":"BMJ"},{"key":"10.1053\/j.gastro.2025.12.040_bib95","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s11136-009-9496-9","article-title":"Development of physical and mental health summary scores from the Patient-Reported Outcomes Measurement Information System (PROMIS) global items","volume":"18","author":"Hays","year":"2009","journal-title":"Qual Life Res"},{"key":"10.1053\/j.gastro.2025.12.040_bib97","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1053\/j.gastro.2022.12.009","article-title":"Negative impact of disorders of gut-brain interaction on health-related quality of life: results from the Rome Foundation Global Epidemiology Survey","volume":"164","author":"Knowles","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2025.12.040_bib98","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1053\/j.gastro.2020.04.014","article-title":"Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome Foundation Global Study","volume":"160","author":"Sperber","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2025.12.040_bib99","article-title":"Validation of the PROMIS Global Physical and Mental Health Scale for Gastrointestinal Disorders: a large-scale cross-sectional survey","author":"Apputhurai","year":"2025","journal-title":"Neurogastroenterol Motil"},{"key":"10.1053\/j.gastro.2025.12.040_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpsychores.2024.111654","article-title":"Confirmatory validation of the patient health questionnaire\u20144 (PHQ-4) for gastrointestinal disorders: a large-scale cross-sectional survey","volume":"180","author":"Apputhurai","year":"2024","journal-title":"J Psychosom Res"},{"key":"10.1053\/j.gastro.2025.12.040_bib101","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1007\/s11136-016-1421-4","article-title":"A systematic review of measurement properties of the instruments measuring health-related quality of life in patients with irritable bowel syndrome","volume":"25","author":"Lee","year":"2016","journal-title":"Qual Life Res"},{"key":"10.1053\/j.gastro.2025.12.040_bib102","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/ajg.2013.401","article-title":"Development of an online library of patient-reported outcome measures in gastroenterology: the GI-PRO database","volume":"109","author":"Khanna","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2025.12.040_bib103","series-title":"Measuring Health: A Review of Quality of Life Measurement Scales","author":"Bowling","year":"2005"},{"key":"10.1053\/j.gastro.2025.12.040_bib104","doi-asserted-by":"crossref","DOI":"10.1111\/nmo.13986","article-title":"Nopal fiber (Opuntia ficus-indica) improves symptoms in irritable bowel syndrome in the short term: a randomized controlled trial","volume":"33","author":"Remes-Troche","year":"2021","journal-title":"Neurogastroenterol Motil"},{"key":"10.1053\/j.gastro.2025.12.040_bib105","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.14309\/ajg.0000000000001149","article-title":"Exploratory comparative effectiveness trial of green kiwifruit, psyllium, or prunes in US Patients With Chronic Constipation","volume":"116","author":"Chey","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2025.12.040_bib106","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1111\/apt.17239","article-title":"Randomised controlled trial: effects of gluten-free diet on symptoms and the gut microenvironment in irritable bowel syndrome","volume":"56","author":"Algera","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2025.12.040_bib107","doi-asserted-by":"crossref","first-page":"973","DOI":"10.14309\/ajg.0000000000001732","article-title":"Optimal design of clinical trials of dietary interventions in disorders of gut-brain interaction","volume":"117","author":"Staudacher","year":"2022","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2025.12.040_bib108","doi-asserted-by":"crossref","DOI":"10.1093\/cdn\/nzy101","article-title":"Within- and between-subject variation in dietary intake of fermentable oligo-, di-, monosaccharides, and polyols among patients with irritable bowel syndrome","volume":"3","author":"Nybacka","year":"2019","journal-title":"Curr Dev Nutr"},{"key":"10.1053\/j.gastro.2025.12.040_bib109","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/ajg.2013.77","article-title":"Design of clinical trials evaluating dietary interventions in patients with functional gastrointestinal disorders","volume":"108","author":"Yao","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2025.12.040_bib110","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1111\/nmo.12466","article-title":"The accuracy of patient-reported measures for GI symptoms: a comparison of real time and retrospective reports","volume":"26","author":"Lackner","year":"2014","journal-title":"Neurogastroenterol Motil"},{"key":"10.1053\/j.gastro.2025.12.040_bib111","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/ajg.2011.358","article-title":"IBS patients show frequent fluctuations between loose\/watery and hard\/lumpy stools: implications for treatment","volume":"107","author":"Palsson","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2025.12.040_bib112","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1207\/S15324796ABM2403_09","article-title":"Capturing momentary, self-report data: a proposal for reporting guidelines","volume":"24","author":"Stone","year":"2002","journal-title":"Ann Behav Med"},{"key":"10.1053\/j.gastro.2025.12.040_bib116","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jclinepi.2017.05.004","article-title":"Series: Pragmatic trials and real world evidence: Paper 7. Safety, quality and monitoring","volume":"91","author":"Irving","year":"2017","journal-title":"J Clin Epidemiol"},{"key":"10.1053\/j.gastro.2025.12.040_bib117","doi-asserted-by":"crossref","first-page":"781","DOI":"10.7326\/0003-4819-141-10-200411160-00009","article-title":"Better reporting of harms in randomized trials: an extension of the CONSORT statement","volume":"141","author":"Ioannidis","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.gastro.2025.12.040_bib118","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1186\/1745-6215-15-335","article-title":"The recording of adverse events from psychological treatments in clinical trials: evidence from a review of NIHR-funded trials","volume":"15","author":"Duggan","year":"2014","journal-title":"Trials"},{"key":"10.1053\/j.gastro.2025.12.040_bib119","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/wps.20153","article-title":"Definition, assessment and rate of psychotherapy side effects","volume":"13","author":"Linden","year":"2014","journal-title":"World Psychiatry"},{"key":"10.1053\/j.gastro.2025.12.040_bib120","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/cpp.1765","article-title":"How to define, find and classify side effects in psychotherapy: from unwanted events to adverse treatment reactions","volume":"20","author":"Linden","year":"2013","journal-title":"Clin Psychol Psychother"},{"key":"10.1053\/j.gastro.2025.12.040_bib121","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/apt.14948","article-title":"Review article: an analysis of safety profiles of treatments for diarrhoea-predominant irritable bowel syndrome","volume":"48","author":"Lacy","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2025.12.040_bib122","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/advances\/nmaa118","article-title":"Perspective: US documentation and regulation of human nutrition randomized controlled trials","volume":"12","author":"Weaver","year":"2021","journal-title":"Adv Nutr"},{"issue":"Suppl 1","key":"10.1053\/j.gastro.2025.12.040_bib124","doi-asserted-by":"crossref","first-page":"56","DOI":"10.2106\/JBJS.K.01412","article-title":"The dangers of stopping a trial too early","volume":"94","author":"Briel","year":"2012","journal-title":"J Bone Joint Surg Am"},{"key":"10.1053\/j.gastro.2025.12.040_bib125","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.c723","article-title":"The quality of reports of randomised trials in 2000 and 2006: comparative study of articles indexed in PubMed","volume":"340","author":"Hopewell","year":"2010","journal-title":"BMJ"},{"key":"10.1053\/j.gastro.2025.12.040_bib126","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0140-6736(05)71879-1","article-title":"Epidemiology and reporting of randomised trials published in PubMed journals","volume":"365","author":"Chan","year":"2005","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2025.12.040_bib127","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.euroneuro.2019.10.007","article-title":"Be positive about negatives-recommendations for the publication of negative (or null) results","volume":"29","author":"Bespalov","year":"2019","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1053\/j.gastro.2025.12.040_bib128","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000251","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials","volume":"7","author":"Schulz","year":"2010","journal-title":"PLoS Med"},{"key":"10.1053\/j.gastro.2025.12.040_bib129","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jclinepi.2021.09.006","article-title":"Inadequate reporting of participants eligible for randomized controlled trials\u2014a systematic review and meta-analysis","volume":"140","author":"Turjeman","year":"2021","journal-title":"J Clin Epidemiol"},{"key":"10.1053\/j.gastro.2025.12.040_bib130","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1590\/2176-9451.20.3.013-015.ebo","article-title":"CONSORT: when and how to use it","volume":"20","author":"Falci","year":"2015","journal-title":"Dental Press J Orthod"},{"key":"10.1053\/j.gastro.2025.12.040_bib131","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1001\/jama.2022.21022","article-title":"Guidelines for reporting outcomes in trial reports: the CONSORT-Outcomes 2022 Extension","volume":"328","author":"Butcher","year":"2022","journal-title":"JAMA"},{"key":"10.1053\/j.gastro.2025.12.040_bib132","doi-asserted-by":"crossref","first-page":"663","DOI":"10.7326\/0003-4819-134-8-200104170-00012","article-title":"The revised CONSORT statement for reporting randomized trials: explanation and elaboration","volume":"134","author":"Altman","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.gastro.2025.12.040_bib133","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1001\/jama.285.15.1987","article-title":"The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials","volume":"285","author":"Moher","year":"2001","journal-title":"JAMA"},{"key":"10.1053\/j.gastro.2025.12.040_bib134","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jclinepi.2016.11.016","article-title":"The minimal clinically important difference raised the significance of outcome effects above the statistical level, with methodological implications for future studies","volume":"82","author":"Angst","year":"2017","journal-title":"J Clin Epidemiol"},{"key":"10.1053\/j.gastro.2025.12.040_bib135","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/ene.13941","article-title":"The minimum clinically important difference: which direction to take","volume":"26","author":"Draak","year":"2019","journal-title":"Eur J Neurol"},{"key":"10.1053\/j.gastro.2025.12.040_bib136","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1179\/2042618612Y.0000000001","article-title":"Clinimetrics corner: a closer look at the minimal clinically important difference (MCID)","volume":"20","author":"Wright","year":"2012","journal-title":"J Man Manip Ther"},{"key":"10.1053\/j.gastro.2025.12.040_bib137","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/S0895-4356(96)00207-7","article-title":"The minimal important difference: who's to say what is important?","volume":"49","author":"Wright","year":"1996","journal-title":"J Clin Epidemiol"},{"key":"10.1053\/j.gastro.2025.12.040_bib138","doi-asserted-by":"crossref","first-page":"109","DOI":"10.4103\/2229-3485.83221","article-title":"Intention-to-treat concept: a review","volume":"2","author":"Gupta","year":"2011","journal-title":"Perspect Clin Res"},{"key":"10.1053\/j.gastro.2025.12.040_bib139","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0376-8716(02)00111-4","article-title":"Intention-to-treat meets missing data: implications of alternate strategies for analyzing clinical trials data","volume":"68","author":"Nich","year":"2002","journal-title":"Drug Alcohol Depend"},{"key":"10.1053\/j.gastro.2025.12.040_bib140","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1191\/1740774504cn032oa","article-title":"Are missing outcome data adequately handled? A review of published randomized controlled trials in major medical journals","volume":"1","author":"Wood","year":"2004","journal-title":"Clin Trials"},{"key":"10.1053\/j.gastro.2025.12.040_bib141","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.c2697","article-title":"Modified intention to treat reporting in randomised controlled trials: systematic review","volume":"340","author":"Abraha","year":"2010","journal-title":"BMJ"},{"key":"10.1053\/j.gastro.2025.12.040_bib142","doi-asserted-by":"crossref","first-page":"144","DOI":"10.4103\/2229-3485.184823","article-title":"Common pitfalls in statistical analysis: intention-to-treat versus per-protocol analysis","volume":"7","author":"Ranganathan","year":"2016","journal-title":"Perspect Clin Res"},{"key":"10.1053\/j.gastro.2025.12.040_bib143","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/nep.13709","article-title":"Intention to treat and per protocol analysis in clinical trials","volume":"25","author":"Tripepi","year":"2020","journal-title":"Nephrology (Carlton)"},{"key":"10.1053\/j.gastro.2025.12.040_bib144","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1093\/ndt\/gfp732","article-title":"Sample size calculations: basic principles and common pitfalls","volume":"25","author":"Noordzij","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.gastro.2025.12.040_bib145","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ijsu.2011.10.001","article-title":"CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials","volume":"10","author":"Moher","year":"2012","journal-title":"Int J Surg"},{"key":"10.1053\/j.gastro.2025.12.040_bib146","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jclinepi.2015.05.023","article-title":"An analysis of protocols and publications suggested that most discontinuations of clinical trials were not based on preplanned interim analyses or stopping rules","volume":"69","author":"Stegert","year":"2016","journal-title":"J Clin Epidemiol"}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001650852600123X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001650852600123X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T08:19:23Z","timestamp":1786349963000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001650852600123X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":133,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S001650852600123X"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2025.12.040","relation":{},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design of Treatment Trials for Disorders of Gut\u2013Brain Interaction","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.gastro.2025.12.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Gastroenterological Association Institute.","name":"copyright","label":"Copyright"}]}}